BRIGHT Institute, Molecular Imaging Center, Mallinckrodt Institute of Radiology, Department of Chemistry, Washington University School of Medicine , Box 8225, 510 South Kingshighway Boulevard, St. Louis, Missouri 63110, United States.
Org Lett. 2012 Jul 20;14(14):3568-71. doi: 10.1021/ol300728a. Epub 2012 Jul 5.
Nucleoside analogues, such as penciclovir, ganciclovir, acyclovir, and their fluoro-substituted derivatives, have wide utility as antivirals. Among these analogues, FHBG ((18)F-Fluorohydroxybutylguanine) is a well-validated PET (positron emission tomography) probe for monitoring reporter gene expression. To evaluate whether or not imposing rigidity into the flexible side chain of FHBG 4 could also impact its interaction, with amino acid residues within the binding site of HSV1-TK (Herpes Simplex Virus-1 Thymidine Kinase), thus influencing its cytotoxic activity. Herein, the synthesis of a new fluorinated nucleoside analogue 6 (conceived via ligand-docking studies) is reported. Agent 6 demonstrates selective activity against HeLa cells stably transfected with mutant HSV1-sr39TK and is also 47-fold more potent than FHBG.
核苷类似物,如喷昔洛韦、更昔洛韦、阿昔洛韦及其氟取代衍生物,作为抗病毒药物有广泛的用途。在这些类似物中,FHBG((18)F-氟羟丁基鸟嘌呤)是一种经过充分验证的 PET(正电子发射断层扫描)探针,可用于监测报告基因的表达。为了评估将 FHBG 4 的柔性侧链固定是否也会影响其与 HSV1-TK(单纯疱疹病毒 1 胸苷激酶)结合位点内氨基酸残基的相互作用,从而影响其细胞毒性活性。在此,报告了一种新的氟化核苷类似物 6 的合成(通过配体对接研究设想)。该试剂 6 对稳定转染突变型 HSV1-sr39TK 的 HeLa 细胞具有选择性活性,并且比 FHBG 强 47 倍。